Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free SVA Stock Alerts

Sinovac Biotech (SVA) Competitors

Sinovac Biotech logo
$6.47 0.00 (0.00%)
As of 07/2/2026
Compare

SVA vs. TRVI, KOD, BHVN, IMNM, and PHVS

Should you buy Sinovac Biotech stock or one of its competitors? MarketBeat compares Sinovac Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sinovac Biotech include Trevi Therapeutics (TRVI), Kodiak Sciences (KOD), Biohaven (BHVN), Immunome (IMNM), and Pharvaris (PHVS). These companies are all part of the "med - biomed/gene" industry.

How does Sinovac Biotech compare to Trevi Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Sinovac Biotech's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sinovac BiotechN/A N/A N/A
Trevi Therapeutics N/A -24.53%-23.37%

Trevi Therapeutics has lower revenue, but higher earnings than Sinovac Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A
Trevi TherapeuticsN/AN/A-$42.76M-$0.32N/A

Sinovac Biotech has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Trevi Therapeutics has a consensus target price of $22.67, suggesting a potential upside of 26.28%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Trevi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Trevi Therapeutics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for Trevi Therapeutics and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.00 equaled Trevi Therapeutics'average media sentiment score.

Company Overall Sentiment
Sinovac Biotech Neutral
Trevi Therapeutics Neutral

95.8% of Trevi Therapeutics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Trevi Therapeutics beats Sinovac Biotech on 9 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

89.1% of Kodiak Sciences shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sinovac Biotech's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -253.85% -81.48%
Sinovac Biotech N/A N/A N/A

Kodiak Sciences has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Kodiak Sciences currently has a consensus price target of $42.14, suggesting a potential upside of 13.84%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Kodiak Sciences is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Sinovac Biotech has higher revenue and earnings than Kodiak Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.17N/A
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A

In the previous week, Kodiak Sciences had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for Kodiak Sciences and 0 mentions for Sinovac Biotech. Kodiak Sciences' average media sentiment score of 0.00 equaled Sinovac Biotech'saverage media sentiment score.

Company Overall Sentiment
Kodiak Sciences Neutral
Sinovac Biotech Neutral

Summary

Kodiak Sciences beats Sinovac Biotech on 7 of the 11 factors compared between the two stocks.

How does Sinovac Biotech compare to Biohaven?

Biohaven (NYSE:BHVN) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Biohaven currently has a consensus price target of $21.63, indicating a potential upside of 34.74%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven
2 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.67
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Biohaven has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, Biohaven had 3 more articles in the media than Sinovac Biotech. MarketBeat recorded 3 mentions for Biohaven and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.00 beat Biohaven's score of -0.25 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Biohaven Neutral
Sinovac Biotech Neutral

88.8% of Biohaven shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sinovac Biotech's return on equity of 0.00% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
BiohavenN/A -866.46% -137.99%
Sinovac Biotech N/A N/A N/A

Sinovac Biotech has higher revenue and earnings than Biohaven.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiohavenN/AN/A-$738.82M-$5.67N/A
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A

Summary

Biohaven beats Sinovac Biotech on 8 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Immunome?

Sinovac Biotech (NASDAQ:SVA) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, Immunome had 7 more articles in the media than Sinovac Biotech. MarketBeat recorded 7 mentions for Immunome and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.00 beat Immunome's score of -0.12 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Sinovac Biotech Neutral
Immunome Neutral

Sinovac Biotech has higher revenue and earnings than Immunome.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A
Immunome$6.94M390.01-$212.39M-$2.38N/A

44.6% of Immunome shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sinovac Biotech's return on equity of 0.00% beat Immunome's return on equity.

Company Net Margins Return on Equity Return on Assets
Sinovac BiotechN/A N/A N/A
Immunome N/A -51.15%-47.32%

Sinovac Biotech has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Immunome has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market.

Immunome has a consensus target price of $33.17, indicating a potential upside of 38.77%. Given Immunome's stronger consensus rating and higher probable upside, analysts plainly believe Immunome is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Immunome
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.85

Summary

Immunome beats Sinovac Biotech on 7 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Pharvaris?

Sinovac Biotech (NASDAQ:SVA) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Sinovac Biotech's return on equity of 0.00% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
Sinovac BiotechN/A N/A N/A
Pharvaris N/A -67.56%-61.13%

Pharvaris has a consensus price target of $49.64, suggesting a potential upside of 49.42%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe Pharvaris is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Pharvaris
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69

In the previous week, Pharvaris had 15 more articles in the media than Sinovac Biotech. MarketBeat recorded 15 mentions for Pharvaris and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.00 beat Pharvaris' score of -0.44 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Sinovac Biotech Neutral
Pharvaris Neutral

Sinovac Biotech has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, indicating that its share price is 334% less volatile than the broader market.

Sinovac Biotech has higher revenue and earnings than Pharvaris.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A
PharvarisN/AN/A-$198.79M-$3.18N/A

Summary

Sinovac Biotech beats Pharvaris on 6 of the 10 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SVA vs. The Competition

Export
MetricSinovac BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$644.66M$3.74B$6.92B$12.59B
Dividend YieldN/A2.16%2.66%6.52%
P/E RatioN/A21.6327.3524.81
Price / Sales1.67179.77507.7389.92
Price / Cash11.8964.1829.6549.23
Price / Book0.078.5811.066.50
Net Income-$59.68M$23.68M$3.57B$336.03M
7 Day PerformanceN/A4.17%2.56%2.68%
1 Month PerformanceN/A16.07%7.39%5.50%
1 Year PerformanceN/A63.53%34.13%25.01%

Sinovac Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVA
Sinovac Biotech
0.6603 of 5 stars		$6.47
flat		N/AN/A$644.66M$386.01MN/A3,008
TRVI
Trevi Therapeutics
2.1793 of 5 stars		$17.43
+0.3%		$22.90
+31.4%		+204.1%$2.47BN/AN/A20
KOD
Kodiak Sciences
0.9638 of 5 stars		$36.00
-2.8%		$42.14
+17.1%		+873.2%$2.32BN/AN/A90
BHVN
Biohaven
3.0557 of 5 stars		$14.92
+0.9%		$22.27
+49.3%		+8.9%$2.23BN/AN/A239
IMNM
Immunome
2.976 of 5 stars		$19.75
+2.2%		$33.17
+67.9%		+171.1%$2.19B$6.94MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 7/6/2026 by MarketBeat.com Staff.
From Our Partners
Amazon, Google, Meta, and Microsoft just committed $700 billion
Amazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...
True Market Insiders | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...
Eagle Publishing | Sponsoredtc pixel
Forget SpaceX, this is Elon’s Next Breakthrough
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Elon’s New Currency (BUY NOW)
Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...
InvestorPlace | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel